S7 Sciences
🇺🇸⌄
21+

Restricted research comparison

Before entering S7 Sciences

Please confirm both statements below. Access is limited to adults who understand the strict research-use restriction applied to the third-party product listings compared on this site.

Required confirmations
I cannot confirm — exit site

Important safety information: S7 Sciences is an affiliate comparison site, not a seller or medical provider. Linked products are not intended for injection or other administration. Please review the complete Terms of Use.

Independent affiliate comparison · Research use only · Not medical advice
S7 SciencesS7 Sciences
ProductsOffersCalculatorCOAResourcesSocial MediaAboutContactAffiliatesInternational Vendors
Comparison Cart0
Comparison cart
0 items

No products added yet.

Open full comparison cart
🇺🇸⌄

The selected language applies across the complete S7 Sciences site. Exact product names, vendor names, strengths, prices, coupon codes, source titles, authors, quotations, and destination links remain unchanged.

ProductsOffersCalculatorCOAResourcesSocial MediaAboutContactAffiliatesInternational Vendors
🇺🇸⌄
Resources/Featured article

A randomized study illustrates why a broad benefit claim must be checked against each measured outcome.

By S7 Sciences Research DeskUpdated October 21, 20262 min read
S7 Sciences
The short version

A positive result on some drinking measures does not mean that every measure improved or that lasting recovery was established.

Featured original sourceS7 adaptation and commentary

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial

Christian S. Hendershot, Michael P. Bremmer, Michael B. Paladino and colleagues

JAMA Psychiatry · Online February 12, 2025; April 2025 issue

The article below is an original S7 Sciences summary and analysis. The quoted passage is brief and attributed; the complete original remains with its author and publisher.

Read the complete original source

Start with the actual study question

Hendershot and colleagues randomized 48 adults with alcohol use disorder to semaglutide or placebo in a nine-week blinded phase 2 trial. Participants were not seeking alcohol treatment. The primary outcome involved a laboratory drinking task; complete before-and-after data for that analysis were available for 25 participants.

The findings were selective

Semaglutide reduced laboratory consumption and drinks per drinking day, with lower reported craving. Average drinks per calendar day and the number of drinking days did not significantly change. The small sample and short follow-up limit conclusions. The paper, published in 2025, called for larger trials.

Quantity, frequency and craving are separate questions

An everyday analogy is spending: a person might spend less on each shopping trip without shopping on fewer days. Those measures can move differently without contradiction. In a research headline, identify the exact outcome before accepting a broad word such as “reduces.” Then check whether the reported comparison was the primary question or an exploratory observation.

Count the participants in each analysis

The number enrolled is not automatically the denominator behind every result. Look for missing observations, exclusions and the handling of incomplete measurements. A reader should be able to explain whose data support the headline. Uncertainty deserves more attention when only a subset supplies a central measurement.

Keep the inference within the evidence

The full original paper was reviewed. Its results do not establish durable recovery, prevention of relapse or equivalence for a research-vial product. This focused explanation is not a comprehensive review of every later study and provides no personal treatment plan. The illustration depicts a research question, not an established benefit.

Evidence summary, not treatment guidance

This article is educational and does not contain medical advice, dosing, administration, or cycling instructions. Research-use-only products are not intended for human or veterinary use.

Primary and authoritative sources

Read the evidence behind this article.

Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical TrialChristian S. Hendershot, Michael P. Bremmer, Michael B. Paladino and colleaguesJAMA Psychiatry

Full open-access article reviewed, including analysis denominators and limitations. DOI: 10.1001/jamapsychiatry.2024.4789; PMID: 39937469. NIH-supported investigator-initiated research.

Back to weekly resources
S7 Sciences

An independent price and documentation index for research peptide listings from third-party vendors.

A Sunset 7 Company
@s7sciences on Instagram

Navigate

ProductsOffersComparison CartConcentration CalculatorCOAResourcesSocial MediaAboutContactAffiliatesInternational Vendors

Information

FAQTermsPrivacyDocumentationVendor & Lab LocationsLocal Pickup · By Appointmentsupport@s7sciences.com

Legal and research-use notice

S7 Sciences does not manufacture, sell, process payment for, or fulfill the linked products. Purchases are completed directly with independent third-party vendors under their own terms and policies.

S7 Sciences may earn a commission from purchases made through clearly labeled links. Vendor prices and documents can change; verify the final listing, lot, COA, shipping, and terms before purchasing.

As an Amazon Associate I earn from qualifying purchases.

Linked materials are presented for laboratory research reference only—not human or veterinary use. This site does not provide medical advice. Please consult a licensed physician before considering or beginning a medical-grade peptide program. Nothing here is dosing guidance or a statement of safety, efficacy, or sterility.

© 2026 S7 SciencesAffiliate relationships disclosed · Prices checked October 4, 2026